ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network-Reference-Cited by-同舟云学术

ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network

Published:2023-12-20 Issue:24 Volume:15 Page:14996-15024
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Qian Hongyan¹,Ji Rui²,Shen Cheng³,Wei Yinze⁴,Sheng Chenyi⁵,Ni Qichao⁵,Pan Jing⁶,Chi Yifan⁶,You Huan⁶,Miao Ying⁶,Shi Minxin⁷,Huang Xianghua⁷,Shen Aiguo¹

Affiliation:

1. Cancer Research Center Nantong, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China

2. Department of Gynecology Oncology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China

3. Department of Computer Science and Engineering, Tandon School of Engineering, New York University, Brooklyn, NY 11201, USA

4. Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China

5. Department of Breast Surgery, Affiliated Hospital of Nantong University, Nantong 226001, China

6. School of Medicine, Nantong University, Nantong 226001, China

7. Department of Surgery, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference42 articles.

1. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.;Chen;Chin Med J (Engl),2022

2. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry andhybridisation database containing results from 199 300 patients.;Miller;J Pathol Clin Res,2018

3. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.;Pal;Breast Cancer Res Treat,2021

4. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.;Takabe;Sci Rep,2019

5. Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer.;Costa;J Pers Med,2021